PL378748A1 - Use of ep2 selective receptor agonists in medical treatment - Google Patents

Use of ep2 selective receptor agonists in medical treatment

Info

Publication number
PL378748A1
PL378748A1 PL378748A PL37874804A PL378748A1 PL 378748 A1 PL378748 A1 PL 378748A1 PL 378748 A PL378748 A PL 378748A PL 37874804 A PL37874804 A PL 37874804A PL 378748 A1 PL378748 A1 PL 378748A1
Authority
PL
Poland
Prior art keywords
medical treatment
receptor agonists
selective receptor
selective
agonists
Prior art date
Application number
PL378748A
Other languages
Polish (pl)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL378748A1 publication Critical patent/PL378748A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL378748A 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment PL378748A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04

Publications (1)

Publication Number Publication Date
PL378748A1 true PL378748A1 (en) 2006-05-15

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378748A PL378748A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment

Country Status (14)

Country Link
EP (1) EP1601351A1 (en)
JP (1) JP2006519250A (en)
KR (1) KR20050105511A (en)
CN (1) CN1859903A (en)
AU (1) AU2004216898A1 (en)
BR (1) BRPI0408061A (en)
CA (1) CA2518193A1 (en)
CL (1) CL2004000412A1 (en)
MX (1) MXPA05009398A (en)
NZ (1) NZ541828A (en)
PL (1) PL378748A1 (en)
TW (1) TW200424176A (en)
WO (1) WO2004078169A1 (en)
ZA (1) ZA200506532B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
EP2422814A1 (en) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
CA2647201C (en) 2006-03-24 2016-03-08 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
EA200970067A1 (en) 2006-07-28 2009-08-28 Пфайзер Продактс Инк. AGONISTS EP2
MX2009004164A (en) * 2006-10-20 2009-10-13 Childrens Medical Center Method to enhance tissue regeneration.
CA2696995C (en) * 2007-08-21 2017-11-21 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
ES2718813T3 (en) 2008-03-12 2019-07-04 Ube Industries Pyridylaminoacetic acid compound
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
DK2415763T3 (en) 2009-03-30 2016-03-07 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
WO2011030872A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Sulfonamide compounds
JP2011057633A (en) * 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
WO2011030871A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 N-substituted heteroaryl compounds
WO2011030873A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Benzyl compounds
WO2011030865A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Substituted zenzyl compounds
WO2011030864A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Aniline compounds
EP2476678A4 (en) * 2009-09-11 2013-02-20 Ube Industries Substituted carbonyl compounds
AU2010336248A1 (en) * 2009-12-25 2012-08-02 Ube Industries, Ltd. Aminopyridine compound
WO2013024358A2 (en) 2011-08-18 2013-02-21 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
PT2785834T (en) 2011-12-02 2020-11-13 Fate Therapeutics Inc Enhanced stem cell composition
EP3381456A1 (en) 2011-12-02 2018-10-03 Fate Therapeutics, Inc. Improved methods for treating ischemia
WO2013109991A1 (en) * 2012-01-20 2013-07-25 Acucela Inc. Substituted heterocyclic compounds for disease treatment
JP2015537028A (en) * 2012-11-16 2015-12-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Compositions and methods for skin repair
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9676720B2 (en) 2013-03-28 2017-06-13 Ube Industries, Ltd. Substituted biaryl compound
WO2015175487A1 (en) 2014-05-13 2015-11-19 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN106397149B (en) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 The preparation method of pentafluorobenzaldehyde
CN115636761B (en) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 Oil-soluble surfactant, oil displacement agent and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
ATE390917T1 (en) * 1996-12-20 2008-04-15 Pfizer PREVENTION AND TREATMENT OF SKELETON DISEASES USING EP2 SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
WO2004078169A8 (en) 2005-04-21
CL2004000412A1 (en) 2005-02-04
EP1601351A1 (en) 2005-12-07
TW200424176A (en) 2004-11-16
ZA200506532B (en) 2007-03-28
CA2518193A1 (en) 2004-09-16
MXPA05009398A (en) 2005-12-05
NZ541828A (en) 2008-06-30
WO2004078169A1 (en) 2004-09-16
CN1859903A (en) 2006-11-08
JP2006519250A (en) 2006-08-24
KR20050105511A (en) 2005-11-04
BRPI0408061A (en) 2006-02-14
AU2004216898A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
PL378748A1 (en) Use of ep2 selective receptor agonists in medical treatment
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
PL2625953T3 (en) Teat treatment device and method of use
GB0403969D0 (en) Tissue treatment device
HK1097256A1 (en) Pyrizdazine derivatives and their use as therapeutic agents
EP1793879A4 (en) Medical skin applicator apparatus
IL172418A0 (en) Therapeutic agents useful for treating pain
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
IL204561A (en) Device for treating bodily tissues with medicinal substance
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL180929A0 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
GB0324761D0 (en) Use of compounds in therapy
IL175605A0 (en) Controlled release of topirimate in liquid dosage forms
EP1515725A4 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
PL1638628T3 (en) Blood treating device
PL1838301T3 (en) Use of resiniferatoxin (rtx) for the preparation of an agent for the treatment of pain
EP1757241A4 (en) Surgical treatment device
EP1874310A4 (en) Opioid receptor agonist compounds and their use in treatment of pain
PL397023A1 (en) Therapeutic agent for AIDS treatment
GB0415181D0 (en) Compounds for use in the treatment of infection
IL281624B1 (en) Therapeutic ultrasound treatment system
PL1799283T3 (en) Blood treatment device comprising rod-shaped means for holding articles
EP1767210A4 (en) The medical use of paeoniflorin
GB2419532B (en) Skin treatment device

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)